Impact of Humoral Immune Response on Distribution and Efficacy of Recombinant Adeno-Associated Virus-Derived Acid α-Glucosidase in a Model of Glycogen Storage Disease Type II
- 1 January 2005
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 16 (1) , 68-80
Abstract
Glycogen storage disease type II (GSDII) is a lysosomal storage disease caused by a deficiency in acid α-glucosidase (GAA), and leads to cardiorespiratory failure by the age of 2 years. In this study, we investigate the impact of anti-GAA antibody formation on cross-correction of the heart, diaphragm, and hind-limb muscles from liver-directed delivery of recombinant adeno-associated virus (rAAV)5- and rAAV8-GAA vectors. GAA-/- mice receiving 1 × 1012 vector genomes of rAAV5- or rAAV8-DHBV-hGAA were analyzed for anti-GAA antibody response, GAA levels, glycogen reduction, and contractile function. We demonstrate that restoration of GAA to the affected muscles is dependent on the presence or absence of the antibody response. Immune-tolerant mice had significantly increased enzyme levels in the heart and skeletal muscles, whereas immune-responsive mice had background levels of GAA in all tissues except the diaphragm. The increased levels of activity in immune-tolerant mice correlated with reduced glycogen in the heart and diaphragm and, overall, contractile function of the soleus muscle was significantly improved. These findings highlight the importance of the immune response to rAAV-encoded GAA in correcting GSDII and provide additional understanding of the approach to treatment of GSDII.Keywords
This publication has 38 references indexed in Scilit:
- Phase I Trial of Intranasal and Endobronchial Administration of a Recombinant Adeno-Associated Virus Serotype 2 (rAAV2)-CFTR Vector in Adult Cystic Fibrosis Patients: A Two-Part Clinical StudyHuman Gene Therapy, 2003
- Influence of Vector Dose on Factor IX-Specific T and B Cell Responses in Muscle-Directed Gene TherapyHuman Gene Therapy, 2002
- Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectorsGene Therapy, 2002
- Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transferGene Therapy, 2001
- Risk and Prevention of Anti-factor IX Formation in AAV-Mediated Gene Transfer in the Context of a Large Deletion of F9Molecular Therapy, 2001
- A Novel Recombinant Adeno-Associated Virus Vaccine Induces a Long-Term Humoral Immune Response to Human Immunodeficiency VirusHuman Gene Therapy, 2001
- Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IXMolecular Therapy, 2000
- Induction of Immunity to Antigens Expressed by Recombinant Adeno-Associated Virus Depends on the Route of AdministrationClinical Immunology, 1999
- Recombinant adeno-associated virus purification using novel methods improves infectious titer and yieldGene Therapy, 1999
- Adeno-Associated Virus-Mediated Gene Transfer to the Brain: Duration and Modulation of ExpressionHuman Gene Therapy, 1999